Board Appointment

Deltex Medical Group PLC
31 October 2002


31 October 2002


            Deltex Medical Group plc ('Deltex Medical' / 'Company')

APPOINTMENT OF DIRECTOR



Chichester, UK - Deltex Medical (AIM LSE: DEMG) today announces the appointment
of Andy Hill to the Board as Chief Operating Officer with immediate effect.  He
is taking day to day responsibility for all aspects of Deltex Medical's
operations.



Andy, aged 40, has over 15 years' experience in the medical devices industry
progressing through a variety of sales, marketing and general management roles.
Most recently Andy has been responsible for establishing and growing the
European operations of early stage US medical device businesses such as Perclose
Inc, PercuSurge Inc and Acorn Cardiovascular Inc.  Andy joined Deltex Medical on
an interim basis to manage the transition to direct selling in the UK and to
lead a review of international distribution strategy; he has a BSc in
biochemistry and botany and an MBA.



Commenting on the appointment, Nigel Keen, Chairman of Deltex Medical, said:



'Andy Hill's appointment completes the steps we initiated at the beginning of
the year to focus our business into those areas where the Group operates most
successfully.  Andy brings to us marketing and general management experience
gained from international  high tech medical device companies and he will help
us achieve our drive towards profitability.'



Andy Hill commented:



'I am delighted to have been appointed to the Deltex Medical Board.  The Company
is very well positioned to fully exploit the medical community's growing belief
in the merits of monitoring and optimising the haemodynamic status of critically
ill patients.  Deltex Medical's technology is supported by key thought leaders
in anaesthesia and other medical disciplines, and has clearly been demonstrated
to have a positive impact on patient recovery through extensive clinical study
and evaluation.  Today our devices will be helping more than seventy patients to
recover more fully and quickly. It is our goal to ensure that in future,
thousands of patients around the world will get better quicker every day through
the use of our technology.'



There are no matters to be disclosed under schedule two, paragraph (f) of the
AIM Rules.



                                    - ends -

Enquiries


Deltex Medical Group plc                    01243 774 837
Nigel Keen, Chairman and Chief Executive    [e-mail]
Ewan Phillips, Finance Director             [e-mail]


Financial Dynamics                          020 7831 3113
Francetta Carr                              [e-mail]



Notes for editors

Deltex Medical primarily develops, assembles and markets a cardiac function
monitor and therapy guidance device, the CardioQTM ('CardioQTM'/'Monitor'). The
CardioQTM incorporates the Company's proprietary software and a narrow,
easy-to-use, minimally invasive, disposable oesophageal probe, used for
transmitting and receiving an ultra-sound ('Doppler') signal. By using this
Doppler technology, the CardioQTM provides clinicians with an early warning on
the haemodynamic condition of critically ill patients. This continuous,
real-time monitoring facilitates the administration of fluids or drugs in a
timely fashion and provides an immediate assessment of their impact.

There are already over 700 CardioQTMs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 75 clinical publications on the use of the CardioQ
TM which have repeatedly:-

  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works
  • proved that the CardioQTM works over a variety of types of operation
  • shown that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The Company is also currently developing a number of new products:-

  • the SupraQTM - a monitor based on the CardioQTM technology but using a
    completely non-invasive probe; the prototype is being prepared for clinical
    testing
  • the NeuroQTM - a monitor designed to measure blood flow in the brain; the
    new prototype is in preparation for clinical trials.




                      This information is provided by RNS
            The company news service from the London Stock Exchange